期刊文献+

虚拟表型方法在HIV-1耐药检测中的应用

Applications of virtual phenotype in HIV-1 resistance detection
原文传递
导出
摘要 艾滋病病毒Ⅰ型(HIV-1)耐药性检测,已成为抗病毒治疗中进行合理用药的重要依据。基因型和表型耐药检测是最常用的HIV耐药检测方法,这两种方法的局限性在于:基因型方法不能直接提供药物耐受信息,表型方法比较耗时。根据上述两种方法之间的良好相关性提出的虚拟表型耐药检测方法,尽管也存在不足,但是提供了另外一种方便的得到耐药信息的方法,从而更好地指导抗病毒治疗。 Detection of resistance mutations is becoming important for the clinical management in antiretroviral therapy(ART).Genotypic and phenotypic HIV drug resistance tests are generic methods to detect resistance,but the disadvantages are indirect drug resistance information of genotypic test and time consuming of phenotypic test.Although there is deficiency of virtual phenotype,it provides an easy way to get resistance information to guide therapy.
出处 《中国艾滋病性病》 CAS 2011年第2期188-190,共3页 Chinese Journal of Aids & STD
基金 国家自然科学基金资助项目(No.30830088 30800938) "十一五"重大专项(2008ZX10001-004)~~
关键词 耐药 CUT-OFF值 虚拟表型 Resistance Cut-off value Virtual phenotype
  • 相关文献

参考文献18

  • 1Robert WS and Jonathan MS. HIV-1 Drug Resistance Mutations: an Updated Framework for the Second Decade of HAART[J]. AIDS Reviews, 2008, 10..67-84.
  • 2Winters B, Montaner J, Harrigan P, et al. Determination of clinically relevant cutoffs for HIV-1 phenotypie resistance estimates through a combined analysis of clinical trial and cohort data[J]. Journal of Acquired Immune Deficiency Syndromes, 2008, 48 (1) 26.
  • 3Graham N, Peeters M, Verbiest W, et al. The virtual phenotype is an independent predictor of clinical response, 2001.
  • 4Yuen LK, Ayres A, Littlejohn M, et al. SeqHepB: a sequence a- nalysis program and relational database system for chronic hepatitis B[J]. AntiviralRes, 2007, 75(1): 64- 74.
  • 5成军.要充分重视乙型肝炎病毒耐药专家共识[J].中华实验和临床感染病杂志(电子版),2008,2(2):1-5. 被引量:2
  • 6Tossonian HK, Raffa JD, Grebely J, et al. Primary drug resistance in antiretroviral-naive injection drug users[J]. Int J Infect Dis, 2009, 13(5): 577-583.
  • 7Mazzotta F, I.o Caputo S, Torti C, et al. Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial[J]. J Acquit Immune Defie Syndr, 2003, 32(3) 268-80.
  • 8Gallego O, Martin-Carbonero L, Aguero J, et al. Correlation be- tween rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infectedindividuals[J]. J VirolMethods, 2004, 121(1): 115-8.
  • 9Harrigan PR, Montaner JS, Wegener SA, et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals[J]. Biologically relevant values for resistance testing AIDS, 2001, 15: 1671-1677.
  • 10Geretti, Anna Maria, editor. Antiretroviral Resistance in Clinical Practice[M]. London: Mediseript Ltd, 2006.

二级参考文献25

  • 1慢性乙型肝炎防治指南[J].中华传染病杂志,2005,23(6):421-431. 被引量:824
  • 2[3]Niederau C,Heintges T,Lange S,et al.Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.N Engl J Med,1996,334:1422-1427.
  • 3[4]Lau GK,Piratvisuth T,Luo KX,et al.Peginterferon alfa-2a,lamivudine,and the combination for HBeAg-positive chronic hepatitis B.N Engl J Med,2005,352:2682-2695.
  • 4[5]Liaw YF,Sung JJ,Chow WC,et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease.Rev Gastroenterol Disord,2005,5:178-181.
  • 5[8]Gish RG.Current treatment and future directions in the management of chronic hepatitis B viral infection.Clin Liver Dis,2005,9:541-565.
  • 6[9]Keeffe EB,Dieterich DT,Han SH,et al.A treatment algorithm for the management of chronic hepatitis B virus infection in the United States:an update.Clin Gastroenterol Hepatol,2006,4:936-962.
  • 7[10]Keeffe EB,Zeuzem S,Koff RS,et al.Report of an international workshop:roadmap for management of patients receiving oral therapy for chronic hepatitis B.Clin Gastroenterol Hepatol,2007,5:890-897.
  • 8[11]Lok AS,McMahon BJ.Chronic hepatitis B.Hepatology,2007,45:507-539.
  • 9Huang H, Chopra R, Verdine GL, et al. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science, 1998,282(5394): 1669-1675.
  • 10Balzarini J. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy. Biochem Pharmacol, 1999,58( 1 ): 1-27.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部